Opus Genetics (NASDAQ:IRD – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
Insider & Institutional Ownership
15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Opus Genetics and Co-Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
| Co-Diagnostics | -6,531.77% | -210.99% | -174.97% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 34.75 | -$49.59 million | ($1.35) | -4.42 |
| Co-Diagnostics | $620,000.00 | 12.50 | -$46.90 million | ($10.32) | -0.11 |
Co-Diagnostics has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Opus Genetics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 2.85, suggesting that its stock price is 185% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Opus Genetics and Co-Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
| Co-Diagnostics | 1 | 1 | 1 | 1 | 2.50 |
Opus Genetics presently has a consensus price target of $11.92, indicating a potential upside of 99.72%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 5,981.08%. Given Co-Diagnostics’ higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Opus Genetics.
Summary
Opus Genetics beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
